UBS’s ImmuCell ICCC Stock Holding History

UBS’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$10K	Buy	1,962 +110	+6%	+$514	﹤0.01%	8829
2014 Q2	$8K	Buy	1,852 +852	+85%	+$3.59K	﹤0.01%	9089
2014 Q1	$5K	Sell	1,000 -697	-41%	-$3.03K	﹤0.01%	9522
2013 Q4	$7K	Sell	1,697 -1,625	-49%	-$7.04K	﹤0.01%	9316
2013 Q3	$16K	Buy	3,322 +1,452	+78%	+$5.68K	﹤0.01%	8305
2013 Q2	$7K	Buy	+1,870	New	+$6.7K	﹤0.01%	8980

Other funds holding ICCC

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

SRC

Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return

SKK

Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return

EFS

Essex Financial Services Essex, Connecticut $1.78B AUM 23.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

GSC

Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return

UBS's ICCC Position: Q3 2014 in Review

UBS increased its ImmuCell (ICCC) stake by 5.9% in Q3 2014, buying an estimated $514 and bringing the position to 1,962 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #8829.

UBS first reported a position in ICCC in Q2 2013 and has held it in 6 quarters since. The position peaked at $16K in Q3 2013. 13 funds tracked by Wall St. Rank hold ICCC as of Q3 2014.

UBS held 1,962 shares of ImmuCell worth $10K as of Q3 2014.
UBS bought 110 ImmuCell shares in Q3 2014, an estimated $514.
ImmuCell made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8829 holding.
UBS first reported a position in ImmuCell in Q2 2013 and has held it in 6 quarters since.
UBS's ImmuCell position peaked at $16K in Q3 2013.
13 funds tracked by Wall St. Rank held ImmuCell as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.